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 36 
A new synthetic route to triaryl pyrrolo[2,3-d]pyrimidines from common 4,6-dichloropyrimidine has 37 
been developed. The triarylated compounds are synthesized by three crosscoupling reactions using three 38 
different catalysts. The introduction of a C-6 aryl group was achieved in a two-step process under 39 
Sonogashira conditions [Pd(dba)2/CuI] followed by intramolecular cyclization, and application of 40 
Suzuki–Miyaura conditions [Pd(PPh3)4; PdCl2(PPh3)2] led to C-4 and C-5 diarylation. This sequence 41 
allows a flexible synthetic approach to highly arylated pyrrolopyrimidines containing different aryl 42 
groups. 43 
 44 
  45 
INTRODUCTION 46 
 47 
Pyrrolo[2,3-d]pyrimidines (IUPAC numbering is used throughout the manuscript), also known as 7-48 
deazapurines, are an important class of heterocyclic compound containing a pyrrole ring with pyrimidine 49 
fused at the α,β-position. The pyrrolo[2,3-d]pyrimidine core is found in a wide range of natural 50 
compounds, including nucleoside antibiotics such as toyocamycin, sangivamycin and tubercidin.[1] Its 51 
wide and versatile spectrum of biological activities has led to its incorporation in synthetic biologically 52 
active compounds such as neurogenesis inductors by GSK-3b inhibition (TWS119, Figure 1),[2] 53 
antitumor (ACK1 inhibitors with IC50 = 0.62 μm, Figure 1),[3] anti-inflammatory agents,[4] and 54 
analgesic derivatives.[5] In addition to these bioapplications, other structurally diverse substituted 55 
purines[6] and 7- deazapurines[7,8] have been studied for their photophysical properties as, for example, 56 
electronic material and blue-light emitters. In recent years, great efforts have been dedicated to the 57 
synthesis of this heterocyclic system and to the devel-opment and functionalization of biologically 58 
active compounds containing the pyrrolo[2,3-d]pyrimidine substructure.[9] 59 
General methods for the preparation of pyrrolopyrimidines remain limited.[10] The majority of 60 
procedures provide C-4 monosubstituted or C-2, N-7 disubstituted compounds and there have been few 61 
general approaches to the functionalization of this heterocycle system.[11] In general, compounds 62 
possessing this nitrogenated scaffold can be prepared from alicyclic reagents in basic media.[12] A 63 
synthesis of pyrrolo[2,3-d]pyrimidines by the cyclization of appropriately substituted pyrrole was 64 
reported by Rashad et al.[13] and Hilmy et al.[14] The standard method entails the introduction of the 65 
pyrrole ring to bridge the pyrimidine at the C-4, C-5 positions. Other previously published synthetic 66 
approaches to pyrrolopyrimidines have used halogenated pyrimidines as the common intermediate, 67 
which are converted into the corresponding aminopyrimidines.[15] The crosscoupling reaction of 68 
aminopyrimidines with vinyl stannanes followed by cyclization furnishes the pyrrolopyrimidines 69 
without functionalization of the five-membered ring.[15] The reaction of 4-amino-5-bromopyrimidine 70 
through ketone α- arylation with acetophenone provides the 6-phenylpyrrolopyrimidine in 62% 71 
yield.[16] Recently, Kopecky and coworkers[3] reported a general route with which to access the 72 
bicyclic structure from 4,6-diamino-5-iodopyrimidine involving an intramolecular palladium-catalyzed 73 
Heck reaction. The cyclization reaction of 2-alkynylanilines constitutes an interesting procedure with 74 
which to obtain 2-substituted indoles, azaindoles or other heterocyclic cores including 75 
pyrrolopyrimidines.[17] However, this intramolecular cyclization requires a base and high temperatures 76 
(180–200 °C).[17,18] 77 
Despite the wide range of methods available for the preparation of pyrrolopyrimidines, very few of them 78 
provide an efficient procedure with which to obtain the heterocyclic system with a range of substituents. 79 
To the best of our knowledge, the limited number of approaches available for the synthesis and 80 
functionalization of pyrrolo[2,3-d]pyrimidines do not include the preparation of 4,5,6-81 
triarylpyrrolopyrimidines. Only 2,4,7-triarylpyrrolo[2,3-d]pyrimidines[19] and 2,6,8-triarylpurines,[20] 82 
possessing optical or adenosine antagonist properties, respectively, have been reported. 83 
.  84 
RESULTS AND DISCUSSION 85 
 86 
With the aim of developing an efficient route that is suitable for the triarylation of pyrrolopyrimidines, 87 
we designed the following general synthesis from the commercially available precursor 4,6-88 
dichloropyrimidine (1; Scheme 1). This synthesis was performed in seven steps by using microwave 89 
irradiation under mild to moderate conditions from stable starting material. 90 
The starting 5-alkynylpyrimidines 4 can be prepared easily by a Sonogashira type alkynylation[21] of 6-91 
chloro-5-iodo-4-(methylamino)pyrimidine by using commercial alkynylbenzenes under microwave 92 
assistance. The use of microwave irradiation under palladium catalysis has been investigated and applied 93 
to organic synthesis in both academia and industry.[22] The Sonogashira reaction is chemoselective and 94 
the yield is not affected by the electronic properties of the 4-substituted aryl alkyne (Scheme 2). The 6-95 
chloro-5-iodo-4-(methylamino)pyrimidine (3) used in this reaction was prepared by nucleophilic 96 
substitution of the 4,6-dichloropyrimidine with methylamine at C-4 followed by iodination under 97 
classical conditions.[17] 98 
The intramolecular cyclization in the presence of base (Cs2CO3) and a catalytic amount of CuI (1 mol-99 
%) under microwave irradiation afforded bicyclic heterocycle 5 in excellent yield with good tolerance of 100 
different substituent groups. These conditions allowed us to work at lower temperatures (100 °C) than 101 
those published by other authors (180–200 °C).[17,18] Applying the same conditions but performing the 102 
cyclization without CuI provided higher yields, showing that the reaction works even better without the 103 
copper catalyst (Scheme 3). The optimized protocol involved treating diarylalkyne with cesium 104 
carbonate in acetonitrile and heating at 100 °C for 30–90 min in a microwave system. Ring closure was 105 
achieved to give the desired product 5 in only one step from the common intermediate 4; the product 106 
was used in the next step without further purification. 107 
In a preliminary study, the direct halogenation of 4-chloropyrrolopyrimidines 5 by using N-108 
bromosuccinimide (NBS) or N-iodosuccinimide (NIS), under microwave assistance, provided the 109 
corresponding 5-bromopyrrolopyrimidines (87%) or 5-iodopyrrolopyrimidines (90%) (Scheme 4). 110 
Replacement of the bromo or iodo group attached at the C-5 position of the pyrrolopyrimidines by using 111 
the corresponding arylboronic acid provided the arylated compounds 9 in yields of 33 or 70%, from the 112 
bromo or iodo derivative, respectively. 113 
In the following step, the isolated 4-chlorodiarylated pyrrolopyrimidines 9 were arylated by using aryl 114 
boronic acids and Suzuki–Miyaura catalysts in 83% yield. This synthetic procedure furnished 115 
triarylpyrrolopyrimidines 8 in seven steps with an overall yield of 12–32%. 116 
With these results in hand, we attempted to generate triarylpyrrolopyrimidines from intermediate 5 by 117 
using an alternative route, reversing the order of arylation of the pyrrolopyrimidines so that arylation 118 
would first take place at C-4 and then at C-5. Thus, 4-arylderivatives 6 were obtained by treatment of 4-119 
chloropyrrolopyrimidines 5 with arylboronic acids under Suzuki–Miyaura cross-coupling conditions[23] 120 
by using a microwave heat source.[24] The reaction yields were good to excellent (91–100%; Table 1), 121 
and the reaction incorporating the phenyl derivatives was found to be chemoselective. This method thus 122 
provides efficient access to diarylated compounds. 123 
Direct arylation of C-5 was not achieved under a wide range of tested conditions. As a result, the 124 
diarylpyrrolopyrimidines were iodinated at the C-5 position by electrophilic substitution with N-125 
iodosuccinimide[25] under microwave radiation at 100 °C with nearly quantitative conversion, very 126 
high yields, and sufficient purity as to obviate the need for a purification step (Table 2). Halogenation at 127 
C-5 was performed regioselectively. Interestingly, analysis of the iodo compounds by 1H NMR 128 
spectroscopy carried out at 30, 100, and 180 days after their preparation showed higher stability at room 129 
temperature when the compounds were stored without a solvent. Following this study, the iodo 130 
compounds in chloroform solution showed complete stability after 30 days at room temperature. It 131 
should be emphasized that carrying out the C-4 arylation of the pyrrolopyrimidines before C-5 132 
iodination avoided the Cl/I exchange that impedes the chemoselective arylation. 133 
The third aryl group at the C-5 position of 4,6-diaryl-5-iodopyrrolo[2,3-d]pyrimidines 7 was introduced 134 
by treatment with arylboronic acids under Suzuki–Miyaura cross-coupling conditions. After workup, a 135 
new iodination process with NIS was carried out, which allowed some additional starting material to be 136 
recovered, separated, and reused. Microwave assistance enabled a rapid synthesis of a variety of triaryl 137 
pyrrolopyrimidines with different substituents. It was clear that meta and para substituents on the 138 
arylboronic acid (Ar2) were well-tolerated, whereas ortho substituents hampered the reaction as a result 139 
of steric hindrance (Table 3, entry 5). The ortho, meta or para substituents of the aryl groups attached at 140 
C-4 of the pyrrolopyrimidine core did not modify the arylation process (Table 3, entries 1, 6 and 9). 141 
Whereas the presence of a substituent of the aryl group linked to C-6 (Table 3, cf. entry 1 with entries 10 142 
and 11) had a significant impact on the rate of the Suzuki–Miyaura reaction, the electron-donating or 143 
withdrawing nature of the substituents was not influential. Increasing the number of equivalents of the 144 
reactant, as well as the reaction time and temperature did not favor the reaction. The optimized 145 
procedure afforded the desired triaryl-substituted pyrrolopyrimidines in 35–50% overall yield in seven 146 
steps, which constitutes a significant improvement on the previously described route. 147 
The molecular structure of the triaryl-substituted pyrrolo[2,3-d]pyrimidine 8k (Table 3, entry 11) was 148 
determined by means of X-ray diffraction studies, and the crystallographic data and structural 149 
refinement parameters have been deposited with the CCDC. Colorless crystals of 8k were obtained by 150 
slow diffusion of hexane over a saturated ethyl acetate solution. The compound crystallized in the prism 151 
space group C2/c. The crystallographic structure and atom numbering are given in Figure 2, which 152 
shows a perspective view of compound 8k. The crystallographic structure reveals the orientation of the 153 
three aryl substituents with respect to the pyrrolopyrimidine system. 154 
 155 
 156 
  157 
CONCLUSIONS 158 
 159 
The chemistry outlined here provides an efficient pathway for the synthesis of triarylated pyrrolo[2,3-160 
d]pyrimidines through three cross-coupling reactions catalyzed by palladium under microwave 161 
irradiation. The high yields obtained in the different steps suggest that this process has considerable 162 
promise for the synthesis of pyrrolopyrimidines bearing three different (or equivalent) arylated 163 
substituents (overall yield 35–50%). This method allows arylation at C-4, C-5 and C-6 of 164 
pyrrolopyrimidines and should be of interest for the synthesis of medicinal and photoactive structures. 165 
  166 
EXPERIMENTAL SECTION 167 
 168 
General: Microwave-assisted reactions were carried out with a Biotage Initiator Microwave synthesis 169 
instrument and the internal temperature was measured by an IR sensor. The reactions were monitored by 170 
thin-layer chromatography (TLC) analysis using silica gel (60 F254) plates. Compounds were visualized 171 
by UV irradiation. Column chromatography was performed with silica gel 60 (230–400 mesh, 0.040–172 
0.063 mm). Melting points (mp) were obtained with a melting point apparatus with a digital 173 
thermometer in open capillary tubes and are reported without correction. IR spectra were obtained with 174 
an FTIR Infrared Spectrophotometer. 1H and 13C NMR spectra were recorded at 250 MHz (13C, 63 175 
MHz), 300 (13C, 75.5 MHz), or 400 MHz (13C, 100 MHz). Chemical shifts (δ) (multiplicity, coupling 176 
constants and integration) are reported in parts per million (ppm) relative to the central peak of the 177 
solvent: CDCl3 [δ = 7.26 (H) and 77.16 (C) ppm], CD3OD [δ = 3.31 (H) and 49.45 (C) ppm], 178 
[D6]DMSO [δ = 2.49 (H) and 39.51 (C) ppm] as internal standards. The following abbreviations are 179 
used for the proton spectra multiplicities: s singlet, d doublet, t triplet, q quadruplet, m multiplet, dd 180 
doublet of doublets, dt doublet of triplets and br. broad signal. Coupling constants (J) are reported in 181 
Hertz (Hz). High-resolution mass spectra (HRMS) were recorded with a time-of-flight mass 182 
spectrometer fitted with either an electrospray (ESI) or atmospheric pressure ionization (APCI). All 183 
reagents were of high quality or were purified before use. Organic solvents were of analytical grade or 184 
were purified by standard procedures. 185 
6-Chloro-N-methylpyrimidin-4-amine (2): To a solution of 4,6-dichloropyrimidine (1; 200 mg, 1.34 186 
mmol) in 2-propanol (1.3 mL), triethylamine (0.22 mL, 1.61 mmol) and MeNH2·HCl (108.8 mg, 1.61 187 
mmol) were added. The reaction was stirred and heated to the reflux temperature of 2-propanol until 188 
complete consumption of the starting material as determined by TLC analysis (4 h). After cooling, the 189 
solvent was removed under vacuo. Water (15 mL) was added and the mixture was extracted with ethyl 190 
 acetate (3  15 mL). The combined organic layers were washed with NH4Cl (10 mL). Evaporation of 191 
the solvent under reduced pressure gave the crude product, which was purified by silica gel column 192 
chromatography (CH2Cl2/ethyl acetate, 6:4) to afford 2 (150.7 mg, 1.05 mmol, 78%) as a white solid, 193 
m.p. 136–138 °C (EtOAc) [136–138 °C (hexane)].[26] Rf = 0.22 (CH2Cl2/ethyl acetate, 6:4). IR (ATR 194 
diamond): ν˜ = 3246, 3083, 2967, 1619, 1568, 1429, 1384, 1329, 1227, 1143, 1092, 976, 887, 834, 741, 195 
708 cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.92 (d, J = 4.3 Hz, 3 H), 5.87 (s, 1 H), 6.33 (s, 1 H), 8.31 196 
(s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 28.3, 99.9, 158.2, 159.8, 164.0 ppm. HRMS (ESI): 197 
calcd. For C5H7ClN3 [M + H]+ 144.0323; found 144.0322. 198 
6-Chloro-5-iodo-N-methylpyrimidin-4-amine (3): A solution of pyrimidine 2 (2 g, 13.9 mmol) in 199 
acetonitrile (30 mL) was transferred to a microwave reaction tube and irradiated in a microwave oven 200 
twice at 100 °C for 15 min with previous addition of NIS (9.4 g, 41.7 mmol). The progress of the 201 
reaction was monitored by TLC (CH2Cl2/ethyl acetate, 6:4). After cooling, the solvent was removed, 202 
then CH2Cl2 (50 mL) was added and the organic layer was washed with aqueous saturated Na2S2O3 203 
 (2  50 mL), and NaOH (10%,  2  50 mL). Evaporation of the solvent under reduced pressure gave the 204 
crude product, which was purified by recrystallization from ethanol (20 mL) to afford 3 (3.27 g, 12.1 205 
mmol, 87%) as paleyellow crystals; m.p. 146–148 °C (EtOH). Rf = 0.50 (CH2Cl2/ethyl acetate, 6:4). IR 206 
(ATR diamond): ν˜ = 3292, 2936, 1557, 1499, 1389, 1326, 1263, 1237, 1179, 1122, 1080, 1001, 888, 207 
762 cm–1. 1H NMR (250 MHz, CDCl3): δ = 3.06 (d, J = 4.9 Hz, 3 H), 5.64 (s, 1 H), 8.24 (s, 1 H) ppm. 208 
13C NMR (63 MHz, CDCl3): δ = 29.45, 79.6, 157.3, 162.2, 163.0 ppm. HRMS (ESI): calcd. for 209 
C5H6ClIN3 [M + H]+ 269.9289; found 269.9291. 210 
 211 
General Procedure A (Sonogashira Coupling): A mixture containing 3 (1.0 mmol), alkyne (2.0 212 
mmol), Pd(dba)2 (0.03 mmol), tri(2-furyl) phosphine (0.06 mmol), and CuI (0.04 mmol) in anhydrous 213 
THF (1 mL) and anhydrous triethylamine (3.5 mL) was transferred to a microwave reaction tube and 214 
irradiated in a microwave oven at 100 °C for 30 min. The progress of the reaction was monitored by 215 
TLC. After cooling, the mixture was diluted with aqueous saturated NH4Cl (15 mL) and the aqueous 216 
phase was extracted with  ethyl acetate (3  20 mL). The combined organic phases were dried with 217 
MgSO4 and filtered through Celite. Evaporation of the solvent under reduced pressure gave the crude 218 
product, which was purified by silica gel column chromatography. 219 
 220 
6-Chloro-N-methyl-5-(2-phenylethynyl)pyrimidin-4-amine (4a); General Procedure A: The 221 
reaction was carried out by following general procedure A starting from the iodinated pyrimidine 3 (1 g, 222 
3.71 mmol) and phenylacetylene (0.82 mL, 7.42 mmol). The crude product was purified by silica gel 223 
column chromatography (petroleum ether/CH2Cl2/acetone, 8:1:1) followed by recrystallization 224 
(CH2Cl2/pentane) to afford 4a (842.2 mg, 3.46 mmol, 93%) as a white solid; m.p. 113–115 °C 225 
(pentane). Rf = 0.28 (petroleum ether/ CH2Cl2/acetone, 8:1:1). IR (ATR diamond): ν˜ = 3397, 1564, 226 
1490.1392, 1274, 1230, 1138, 1088, 906, 848, 749, 684 cm–1. 1H NMR (400 MHz, CDCl3): δ = 3.12 227 
(d, J = 5.0 Hz, 3 H), 5.76 (s, 1 H), 7.34–7.44 (m, 3 H), 7.51–7.60 (m, 2 H), 8.35 (s, 1 H) ppm. 13C NMR 228 
(100 MHz, CDCl3): δ = 28.6, 79.6, 101.0, 102.3, 122.0, 128.7, 129.5, 131.8, 156.2, 159.2, 163.0 ppm. 229 
HRMS (ESI): calcd. For C13H11ClN3 [M + H]+ 244.0636; found 244.0637. 230 
 231 
6-Chloro-5-[2-(4-methoxyphenyl)ethynyl]-N-methylpyrimidin-4-amine (4b): The reaction was 232 
carried out by following general procedure A starting from the iodinated pyrimidine 3 (150 mg, 0.56 233 
mmol) and 1-ethynyl-4-methoxybenzene (147.1 mg, 1.11 mmol). The crude product was purified by 234 
silica gel column chromatography (petroleum ether/CH2Cl2/acetone, 70:15:15) followed by 235 
recrystallization (CH2Cl2/pentane) to afford 4b (143.8 mg, 0.53 mmol, 94%) as a white solid; m.p. 131–236 
133 °C (pentane). Rf = 0.30 (petroleum ether/CH2Cl2/acetone, 70:15:15). IR (ATR diamond): ν˜ = 237 
3312, 2927, 2202, 1564, 1504, 1460, 1388, 1352, 1278, 1251, 1170, 1137.1086, 1031, 902, 831, 779, 238 
731 cm–1. 1H NMR (400 MHz, CDCl3): δ = 3.11 (d, J = 5.0 Hz, 3 H), 3.84 (s, 3 H), 5.75 (s, 1 H), 6.90 239 
(d, J = 8.7 Hz, 2 H), 7.48 (d, J = 8.7 Hz, 2 H), 8.33 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 240 
28.5, 55.5, 78.3, 101.3, 102.5, 114.0, 114.3, 133.3, 156.0, 158.9, 160.6, 162.9 ppm. HRMS (ESI): calcd. 241 
for C14H13ClN3O [M + H]+274.0742; found 274.0743. 242 
 243 
6-Chloro-N-methyl-5-{2-[4-(trifluoromethyl)phenyl]ethynyl}-pyrimidin-4-amine (4c): The reaction 244 
was carried out by following general procedure A starting from the iodinated pyrimidine 3 (150 mg, 245 
0.56 mmol) and 1-ethynyl-4-(trifluoromethylbenzene) (0.2 mL, 1.11 mmol). The crude product was 246 
purified by silica gel column chromatography (petroleum ether/CH2Cl2/acetone, 8:1:1) followed by 247 
recrystallization (CH2Cl2/pentane) to afford 4c (172.7 mg, 0.55 mmol, 99%) as a pale-yellow solid; 248 
m.p. 107–109 °C (pentane). Rf = 0.17 (petroleum ether/CH2Cl2/acetone, 8:1:1). IR (ATR diamond): ν˜ 249 
= 3360, 2925, 1562.1509, 1396, 1322, 1276, 1228, 1167, 1090, 1064, 903, 836, 781, 736 cm–1. 1H 250 
NMR (400 MHz, CDCl3): δ = 3.13 (d, J = 5.0 Hz, 3 H), 5.73 (s, 1 H), 7.64 (s, 4 H), 8.37 (s, 1 H) ppm. 251 
13C NMR (100 MHz, CDCl3): δ = 28.6, 81.9, 100.3, 100.6, 123.9 (J = 272 Hz), 125.6 (J = 4 Hz), 125.8 252 
(J = 1 Hz), 131.1 (J = 33 Hz), 132.0, 156.7, 159.8, 163.0 ppm. 19F NMR (376 MHz, CDCl3): δ = –253 
62.94 (CF3) ppm. HRMS (ESI): calcd. for C14H10ClF3N3 [M + H]+ 312.0510; found 312.0511. 254 
 255 
General Procedure B (Cyclization): A solution of alkyne 4a–c (1.0 mmol) and cesium carbonate (1.0 256 
mmol) in acetonitrile (4.5 mL) was transferred to a microwave reaction tube and irradiated in a 257 
microwave oven at 100 °C for the required time. The progress of the reaction was monitored by TLC. 258 
After cooling, the solvent was removed under vacuo. Water (20 mL) was added to the mixture and the 259 
crude material was extracted with ethyl acetate  (3  15 mL). The combined organic phases were washed 260 
with aqueous saturated Na2CO3 (15 mL) and brine (15 mL). Purification was performed by column 261 
chromatography on silica gel to give the corresponding pure product 5. 262 
 263 
4-Chloro-7-methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine (5a): The reaction was carried out by 264 
following general procedure B starting from the alkyne 4a (800 mg, 3.28 mmol) and microwave 265 
irradiation was applied for 30 min. The crude product was purified by silica gel column chromatography 266 
(petroleum ether/CH2Cl2/acetone, 8:1:1) followed by recrystallization (CH2Cl2/pentane) to afford 5a 267 
(795.2 mg, 3.26 mmol, 99%) as a pale-yellow solid; m.p. 151–153 °C (pentane). Rf = 0.18 (petroleum 268 
ether/CH2Cl2/acetone, 8:1:1). IR (ATR diamond): ν˜ = 3741, 2946, 1585, 1541, 1485, 1432, 1405, 269 
1347, 1237, 1184, 1127, 1013, 938, 855, 755, 702 cm–1. 1H NMR (400 MHz, CDCl3): δ = 3.85 (s, 3 270 
H), 6.62 (s, 1 H), 7.44–7.58 (m, 5 H), 8.64 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 30.5, 98.8, 271 
117.7, 129.0, 129.3, 129.4, 130.9, 143.4, 150.6, 151.4, 152.7 ppm. HRMS (ESI): calcd. for 272 
C13H11ClN3 [M + H]+244.0636; found 244.0637. 273 
 274 
4-Chloro-6-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (5b): The reaction was 275 
carried out by following general procedure B starting from the alkyne 4b (267.6 mg, 0.98 mmol) and 276 
microwave irradiation was applied for 90 min. The crude product was purified by silica gel column 277 
chromatography (petroleum ether/ CH2Cl2/acetone, 8:1:1) followed by recrystallization 278 
(CH2Cl2/pentane) to afford 5b (254.2 mg, 0.93 mmol, 95%) as a pale-yellow solid; m.p. 134–136 °C 279 
(pentane). Rf = 0.24 (petroleum ether/CH2Cl2/acetone, 8:1:1). IR (ATR diamond): ν˜ = 3838, 3744, 280 
2950, 1613, 1590, 1544, 1492, 1348, 1291, 1244, 1174, 1133, 1034, 940, 839, 805, 772, 741, 706 cm–1. 281 
1H NMR (400 MHz, CDCl3): δ = 3.83 (s, 3 H), 3.88 (s, 3 H), 6.56 (s, 1 H), 7.00–7.07 (m, 2 H), 7.43–282 
7.50 (m, 2 H), 8.63 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 30.5, 55.6, 98.1, 114.5, 117.8, 283 
123.2, 130.7, 143.4, 150.3, 151.1, 152.7, 160.6 ppm. HRMS (ESI): calcd. for C14H13ClN3O [M + H]+ 284 




4-Chloro-7-methyl-6-[4-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]-pyrimidine (5c): The reaction 289 
was carried out by following general procedure B starting from the alkyne 4c (296.6 mg, 0.95 mmol) 290 
and microwave irradiation was applied for 30 min. The crude product was purified by silica gel column 291 
chromatography (petroleum ether/CH2Cl2/acetone, 8:1:1) followed by recrystallization 292 
(CH2Cl2/pentane) to afford 5c (98%, 290.6 mg, 0.93 mmol) as a yellow solid; m.p. 167–169 °C 293 
(pentane). Rf = 0.27 (petroleum ether/CH2Cl2/ acetone, 8:1:1). IR (ATR diamond): ν˜ = 3743, 2927, 294 
1583, 1544, 1502, 1475, 1447, 1411, 1319, 1262, 1235, 1168, 1119, 1065, 1013, 944, 859, 804, 774, 295 
745, 713 cm–1. 1H NMR (400 MHz, CDCl3): δ = 3.87 (s, 3 H), 6.70 (s, 1 H), 7.68 (d, J = 8.2 Hz, 2 H), 296 
7.79 (d, J = 8.2 Hz, 2 H), 8.68 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 30.6, 99.9, 117.6, 124.0 297 
(J = 272 Hz), 126.1 (J = 4 Hz), 129.6, 131.4 (J = 33 Hz), 134.5 (J = 1 Hz), 141.5, 152.0, 152.9 ppm. 19F 298 
NMR (376 MHz, CDCl3): δ = –62.80 (CF3) ppm. HRMS (ESI): calcd. for C14H10ClF3N3 [M + H]+ 299 
312.0510; found 312.0513. 300 
 301 
General Procedure C (Suzuki–Miyaura Coupling at C-4): Under argon, a mixture of compound 5a–c 302 
(1.0 mmol), boronic acid (1.05 mmol), sodium carbonate (2.0 mmol), and tetrakis(triphenylphosphine) 303 
palladium (0.02 mmol) in a degassed solvent mixture of DME (3.8 mL) and H2O (0.6 mL) was 304 
transferred to a microwave reaction tube and irradiated in a microwave oven at 100 °C for 60 min. The 305 
progress of the reaction was monitored by TLC. After cooling, the mixture was diluted with a mixture of 306 
brine and water (1:1, 20 mL) and the aqueous solution was extracted with ethyl  acetate (3  20 mL). 307 
Evaporation of the solvent under reduced pressure gave the crude product, which was purified by silica 308 
gel column chromatography. 309 
 310 
7-Methyl-6-phenyl-4-(3-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (6a): The reaction was carried out by 311 
following general procedure C starting from 4-chloropyrimidine 5a (450 mg, 1.85 mmol) and 3-312 
tolylboronic acid (263.6 mg, 1.94 mmol). The crude product was purified by silica gel column 313 
chromatography (CH2Cl2/ethyl acetate, 7:3) to afford 6a (507.4 mg, 1.69 mmol, 91%) as a pale-yellow 314 
solid. Rf = 0.32 (CH2Cl2/ethyl acetate, 6:4); m.p. 109–111 °C (ethyl acetate). IR (ATR diamond): ν˜ = 315 
3836, 3741, 2922, 1698, 1560, 1490, 1468, 1396, 1343, 1268, 1217, 1078, 1014, 892, 814, 772, 745 cm–316 
1. 1H NMR (400 MHz, CDCl3): δ = 2.47 (s, 3 H), 3.89 (s, 3 H), 6.86 (s, 1 H), 7.30–7.32 (m, 1 H), 7.40–317 
7.58 (m, 6 H), 7.91–8.01 (m, 2 H), 8.99 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 21.5, 29.9, 318 
99.8, 115.8, 125.9, 128.5, 128.7, 128.8, 129.1, 129.2, 130.6, 138.2, 138.4, 142.7, 151.3, 153.3, 156.8 319 
ppm. HRMS (ESI): calcd. For C20H18N3 [M + H]+ 300.1495; found 300.1498.  320 
 321 
7-Methyl-6-phenyl-4-(2-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (6b): The reaction was carried out by 322 
following general procedure C starting from 4-chloropyrimidine 5a (150 mg, 0.62 mmol) and 2-323 
tolylboronic acid (87.9 mg, 0.65 mmol). The crude product was purified by silica gel column 324 
chromatography (CH2Cl2/ethyl acetate, 8:2) to afford 6b (181.7 mg, 0.61 mmol, 99%) as a white solid. 325 
Rf = 0.45 (CH2Cl2/ethyl acetate, 8:2); m.p. 104–106 °C (ethyl acetate). IR (ATR diamond): ν˜ = 2919, 326 
2849, 1738, 1567, 1541, 1491, 1443, 1404, 1370, 1340, 1320, 1261, 1218, 1135, 1011, 935, 865, 787, 327 
757, 748, 727, 699 cm–1. 1H NMR (300 MHz, CDCl3): δ = 2.39 (s, 3 H), 3.91 (s, 3 H), 6.47 (s, 1 H), 328 
7.27–7.40 (m, 3 H), 7.44–7.56 (m, 6 H), 8.99 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 20.3, 329 
30.1, 99.9, 117.8, 125.8, 128.9, 129.0, 129.1, 129.2, 129.8, 131.1, 131.4, 136.6, 137.5, 142.8, 151.1, 330 
152.9, 159.3 ppm. HRMS (ESI): calcd. for C20H18N3 [M + H]+ 300.1495; found 300.1498. 331 
 332 
7-Methyl-6-phenyl-4-(4-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (6c): The reaction was carried out by 333 
following general procedure C starting from 4-chloropyrimidine 5a (150 mg, 0.62 mmol) and 4-334 
tolylboronic acid (87.9 mg, 0.65 mmol). The crude product was purified by silica gel column 335 
chromatography (CH2Cl2/ethyl acetate, 8:2) to afford 6c (178.4 mg, 0.60 mmol, 96%) as a white solid. 336 
Rf = 0.48 (CH2Cl2/ethyl acetate, 8:2); m.p. 94–96 °C (ethyl acetate). IR (ATR diamond): ν˜ = 3052, 337 
2921, 2855, 1732, 1609, 1554, 1443, 1331, 1261, 1180, 1017, 938, 834, 785, 759, 698 cm–1. 1H NMR 338 
(300 MHz, CDCl3): δ = 2.42 (s, 3 H), 3.85 (s, 3 H), 6.84 (s, 1 H), 7.32 (d, J = 8.0 Hz, 2 H), 7.48–7.51 339 
(m, 5 H), 8.06 (d, J = 8.0 Hz, 2 H), 8.96 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 21.6, 30.2, 340 
100.1, 115.8, 128.9, 128.9, 129.0, 129.3, 129.6, 131.5, 135.6, 140.3, 142.8, 151.4, 153.5, 156.8 ppm. 341 
HRMS (ESI): calcd. For C20H18N3 [M + H]+ 300.1495; found 300.1500. 342 
 343 
4-(4-Methoxyphenyl)-7-methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine (6d): The reaction was 344 
carried out by following general procedure C starting from 4-chloropyrimidine 5a (150 mg, 0.62 mmol) 345 
and 4-methoxyphenylboronic acid (98.2 mg, 0.65 mmol). The crude product was purified by silica gel 346 
column chromatography (CH2Cl2/ethyl acetate, 6:4) to afford 6d (194.5 mg, 0.62 mmol, 100%) as a 347 
yellow solid. Rf = 0.48 (CH2Cl2/ethyl acetate, 8:2); m.p. 174–176 °C (ethyl acetate). IR (ATR 348 
diamond): ν˜ = 3054, 2921, 2845, 1550, 1512, 1439, 1328, 1247, 1172, 1021, 937, 851, 756 cm–1. 1H 349 
NMR (300 MHz, CDCl3): δ = 3.89 (s, 3 H), 3.90 (s, 3 H), 6.87 (s, 1 H), 7.07 (d, J = 8.2 Hz, 2 H), 7.47–350 
7.59 (m, 5 H), 8.17 (d, J = 8.2 Hz, 2 H), 8.96 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 30.1, 351 
55.8, 100.0, 114.3, 115.4, 128.9, 129.0, 129.3, 130.4, 131.0, 131.6, 142.6, 151.4, 153.4, 160.6, 161.3 352 
ppm. HRMS (ESI): calcd. for C20H18N3O [M + H]+ 316.1444; found 316.1447. 353 
 354 
7-Methyl-6-phenyl-4-[4-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]-pyrimidine (6e): The reaction 355 
was carried out by following general procedure C starting from 4-chloropyrimidine 5a (150 mg, 0.62 356 
mmol) and 4-(trifluoromethyl)phenylboronic acid (122.8 mg, 0.65 mmol). The crude product was 357 
purified by silica gel column chromatography (CH2Cl2/ethyl acetate, 8:2) to afford 6e (213.7 mg, 0.60 358 
mmol, 98%) as a beige solid. Rf = 0.57 (CH2Cl2/ethyl acetate, 8:2); m.p. 137–139 °C (ethyl acetate). IR 359 
(ATR diamond): ν˜ = 2960, 2920, 2849, 1736, 1620, 1555, 1493, 1466, 1400, 1327, 1307, 1265, 1219, 360 
1185, 1165, 1103, 1064, 1014, 936, 850, 808, 783, 753, 730, 699 cm–1. 1H NMR (300 MHz, CDCl3): δ 361 
= 3.92 (s, 3 H), 6.85 (s, 1 H), 7.49–7.57 (m, 5 H), 7.81 (d, J = 8.0 Hz, 2 H), 8.28 (d, J = 8.0 Hz, 2 H), 362 
9.02 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 30.3, 99.4, 116.2, 124.2 (J = 271 Hz), 125.8 (J = 363 
4 Hz), 129.0, 129.2, 129.3, 129.4, 131.2, 131.7 (J = 32 Hz), 141.8, 143.8, 151.4, 153.7, 154.9 ppm. 19F 364 
NMR (376 MHz, CDCl3): δ = –62.68 (CF3) ppm. HRMS (ESI): calcd. for C20H15N3F3 [M + H]+ 365 
354.1213; found 354.1214. 366 
 367 
6-(4-Methoxyphenyl)-7-methyl-4-(3-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (6f): The reaction was 368 
carried out by following general procedure C starting from 4-chloropyrimidine 5b (150 mg, 0.55 mmol) 369 
and 3-tolylboronic acid (78.2 mg, 0.58 mmol). The crude product was purified by silica gel column 370 
chromatography (CH2Cl2/ethyl acetate, 8:2) to afford 6f (173.9 mg, 0.53 mmol, 96%) as an offwhite 371 
solid; m.p. 95–97 °C (ethyl acetate). Rf = 0.38 (CH2Cl2/ethyl acetate, 8:2). IR (ATR diamond): ν˜ = 372 
2921, 2855, 2153, 1968, 1615, 1558, 1497, 1442, 1339, 1295, 1252, 1173, 1013, 893, 826, 786, 763, 373 
700 cm–1. 1H NMR (300 MHz, CDCl3): δ = 2.59 (s, 3 H), 3.97 (s, 3 H), 3.98 (s, 3 H), 6.92 (s, 1 H), 374 
7.14 (d, J = 8.8 Hz, 2 H), 7.42 (d, J = 7.5 Hz, 1 H), 7.54 (t, J = 7.5 Hz, 1 H), 7.59 (d, J = 8.8 Hz, 2 H), 375 
8.04–8.14 (m, 2 H), 9.11 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 21.7, 30.1, 55.5, 99.3, 114.4, 376 
116.0, 123.8, 126.1, 128.7, 129.4, 130.6, 130.8, 138.4, 138.9, 142.9, 151.2, 153.3, 156.6, 160.3 ppm. 377 
HRMS (ESI): calcd. for C21H20N3O [M + H]+330.1601; found 330.1602. 378 
 379 
7-Methyl-4-(3-tolyl)-6-[4-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]-pyrimidine (6g): The reaction 380 
was carried out by following genera procedure C starting from 4-chloropyrimidine 5c (150 mg, 0.48 381 
mmol) and 3-tolylboronic acid (68.7 mg, 0.51 mmol). The crude product was purified by silica gel 382 
column chromatography (CH2Cl2/ethyl acetate, 8:2) to afford 6g (169.4 mg, 0.46 mmol, 96%) as an 383 
off-white solid. Rf = 0.43 (CH2Cl2/ethyl acetate, 8:2); m.p. 109–111 °C (ethyl acetate). IR (ATR 384 
diamond): ν˜ = 2921, 2849, 1615, 1551, 1440, 1322, 1160, 1114, 1068, 894, 847, 767, 702 cm–1. 1H 385 
NMR (300 MHz, CDCl3): δ = 2.45 (s, 3 H), 3.87 (s, 3 H), 6.89 (s, 1 H), 7.30 (d, J = 7.6 Hz, 1 H), 7.41 386 
(t, J = 7.6 Hz, 1 H), 7.67 (d, J = 8.2 Hz, 2 H), 7.75 (d, J = 8.2 Hz, 2 H), 7.91 (d, J = 7.6 Hz, 1 H), 7.95 (s, 387 
1 H), 8.99 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 21.7, 30.3, 101.2, 115.8, 124.0 (J = 271 388 
Hz), 125.9 (J = 4 Hz), 126.1, 128.8, 129.5, 129.6, 131.0 (J = 32 Hz), 131.1, 135.1, 138.1, 138.8, 141.1, 389 
151.9, 153.6, 157.6 ppm. 19F NMR (376 MHz, CDCl3): δ = –62.73 (CF3) ppm. HRMS (ESI): calcd. for 390 
C21H17N3F3 [M + H]+ 368.1369; found 368.1371. 391 
 392 
General Procedure D (Aryl Iodination): A solution of 6a–g (1.0 mmol) and NIS (1.1 mmol) in 393 
acetonitrile (4.5 mL) was transferred to a microwave reaction tube and irradiated in a microwave oven at 394 
100 °C for 30 min. The progress of the reaction was monitored by TLC. After cooling, the solvent was 395 
removed under vacuo. Dichloromethane (20 mL) was added and the organic layer was washed with 396 
 aqueous saturated Na2S2O3 (2  16 mL), and NaOH  (10%, 2  16 mL). Evaporation of the solvent 397 
under reduced pressure gave the crude product, which did not require further purification. 398 
 399 
5-Iodo-7-methyl-6-phenyl-4-(3-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (7a): The reaction was carried 400 
out by following general procedure D starting from diaryl pyrimidine 6a (500 mg, 1.67 mmol) to afford 401 
7a (710.0 mg, 1.67 mmol, 100 %) as a yellow solid. Rf = 0.27 (CH2Cl2/ethyl acetate, 8:2); m.p. 188–402 
190 °C (ethyl acetate). IR (ATR diamond): ν˜ = 3045, 2913, 1547, 1439, 1402, 1330, 1254, 1182, 1088, 403 
1020, 958, 915, 783, 764, 708, 682 cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.45 (s, 3 H), 3.77 (s, 3 H), 404 
7.32 (d, J = 7.6 Hz, 1 H), 7.40 (t, J = 7.6 Hz, 1 H), 7.43–7.47 (m, 2 H), 7.49–7.61 (m, 5 H), 8.98 (s, 1 H) 405 
ppm. 13C NMR (100 MHz, CDCl3): δ = 21.6, 30.9, 55.2, 117.3, 127.7, 128.2, 128.8, 129.7, 130.3, 406 
130.9, 131.3, 131.8, 135.8, 137.3, 144.5, 151.1, 152.5, 160.5 ppm. HRMS (ESI): calcd. for C20H17IN3 407 
[M + H]+ 426.0462; found 426.0463. 408 
 409 
5-Iodo-7-methyl-6-phenyl-4-(2-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (7b): The reaction was carried 410 
out by following general procedure D starting from diaryl pyrimidine 6b (150 mg, 0.5 mmol) to afford 411 
7b (211.5 mg, 0.50 mmol, 99 %) as a yellow solid. Rf = 0.51 (CH2Cl2/ethyl acetate, 8:2); m.p. 185–187 412 
°C (ethyl acetate). IR (ATR diamond): ν˜ = 2917, 2849, 1736, 1552, 1438, 1403, 1334, 1242, 1176, 413 
1120, 1089, 951, 887, 796, 765, 725, 701 cm–1. 1H NMR (300 MHz, CDCl3): δ = 2.16 (s, 3 H), 3.79 (s, 414 
3 H), 7.30–7.32 (m, 3 H), 7.37–7.41 (m, 1 H), 7.43–7.46 (m, 2 H), 7.50–7.54 (m, 3 H), 8.98 (s, 1 H) 415 
ppm. 13C NMR (63 MHz, CDCl3): δ = 20.3, 30.9, 54.9, 118.2, 125.3, 128.8, 129.7, 129.9, 130.0, 130.8, 416 
130.9, 135.7, 136.6, 142.8, 136.9, 151.3, 152.0, 162.2 ppm. HRMS (ESI): calcd. for C20H17IN3 [M + 417 
H]+ 426.0462; found 426.0463. 418 
 419 
5-Iodo-7-methyl-6-phenyl-4-(4-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (7c): The reaction was carried 420 
out by following general procedure D starting from diaryl pyrimidine 6c (150 mg, 0.50 mmol) to afford 421 
7c (212.3 mg, 0.50 mmol, 100%) as an off-white solid. Rf = 0.29 (CH2Cl2/ethyl acetate, 8:2); m.p. 204–422 
206 °C (ethyl acetate). IR (ATR diamond): ν˜ = 2960, 2923, 2849, 1612, 1557, 1513, 1480, 1459, 1441, 423 
1335, 1287, 1243, 1224, 1177, 1033, 953, 827, 764, 703 cm–1. 1H NMR (250 MHz, CDCl3): δ = 2.45 424 
(s, 3 H), 3.77 (s, 3 H), 7.32 (d, J = 7.8 Hz, 2 H), 7.39–7.49 (m, 2 H), 7.52–7.55 (m, 3 H), 7.65 (d, J = 7.8 425 
Hz, 1 H), 8.97 (s, 1 H) ppm. 13C NMR (63 MHz, CDCl3): δ = 21.7, 31.0, 55.2, 117.3, 128.5, 128.8, 426 
129.7, 130.9, 131.1, 131.3, 133.2, 139.6, 144.4, 151.1, 152.5, 160.5 ppm. HRMS (ESI): calcd. for 427 
C20H17IN3 [M + H]+ 426.0462; found 426.0463. 428 
 429 
5-Iodo-4-(4-methoxyphenyl)-7-methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine (7d): The reaction 430 
was carried out by following general procedure D starting from diaryl pyrimidine 6d (150 mg, 0.48 431 
mmol) to afford 7d (209.1 mg, 0.48 mmol, 100%) as a yellow solid. Rf = 0.51 (CH2Cl2/ethyl acetate, 432 
8:2); m.p. 196–198 °C (ethyl acetate). IR (ATR diamond): ν˜ = 2921, 2849, 1608, 1556, 1513, 1439, 433 
1321, 1293, 1243, 1174, 1025, 951, 885, 833, 797, 764, 739, 704 cm–1. 1H NMR (300 MHz, CDCl3): δ 434 
= 3.77 (s, 3 H), 3.89 (s, 3 H), 7.04 (d, J = 8.8 Hz, 2 H), 7.41–7.49 (m, 2 H), 7.50–7.58 (m, 3 H), 7.73 (d, 435 
J = 8.8 Hz, 2 H), 8.96 (s, 1 H) ppm. 13C NMR (63 MHz, CDCl3): δ = 31.0, 55.4, 55.5, 113.2, 117.2, 436 
128.5, 128.8, 129.7, 130.9, 131.3, 132.7, 144.4, 151.1, 152.6, 160.0, 161.0 ppm. HRMS (ESI): calcd. for 437 
C20H17IN3O [M + H]+ 442.0411; found 442.0412. 438 
 439 
5-Iodo-7-methyl-6-phenyl-4-[4-(trifluoromethyl)phenyl]-7H-pyrrolo-[2.3-d]pyrimidine (7e): The 440 
reaction was carried out by following general procedure D starting from diaryl pyrimidine 6e (150 mg, 441 
0.42 mmol) to afford 7e (202.4 mg, 0.42 mmol, 99%) as a beige solid. Rf = 0.60 (CH2Cl2/ethyl acetate, 442 
8:2); m.p. 198–200 °C (ethyl acetate). IR (ATR diamond): ν˜ = 2922, 2852, 1733, 1557, 1476, 1440, 443 
1400, 1325, 1244, 1155, 1117, 1107, 1062, 1017, 948, 885, 843, 799, 762.704 cm–1. 1H NMR (400 444 
MHz, CDCl3): δ = 3.79 (s, 3 H), 7.41–7.48 (m, 2 H), 7.51–7.59 (m, 3 H), 7.78 (d, J = 8.4 Hz, 2 H), 7.86 445 
(d, J = 8.4 Hz, 2 H), 8.99 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 30.9, 54.4, 117.4, 124.2 (J = 446 
272 Hz), 124.6 (J = 4 Hz), 128.8, 129.8, 130.7, 130.8, 131.3, 131.4 (J = 32 Hz), 139.4 (J = 1 Hz), 145.0, 447 
151.0, 152.5, 158.5 ppm. 19F NMR (376 MHz, CDCl3): δ = –62.52 (CF3) ppm. HRMS (ESI): calcd. for 448 
C20H14F3IN3 [M + H]+ 480.0179; found 480.0180. 449 
 450 
5-Iodo-6-(4-methoxyphenyl)-7-methyl-4-(3-tolyl)-7H-pyrrolo[2,3-d]-pyrimidine (7f): The reaction 451 
was carried out by following general procedure D starting from diaryl pyrimidine 6f (150 mg, 0.46 452 
mmol) to afford 7f (100%, 207.3 mg, 0.46 mmol) as a yellow solid. Rf = 0.32 (CH2Cl2/acetone, 9:1); 453 
m.p. 179–181 °C (acetone). IR (ATR diamond): ν˜ = 2955, 2918, 2849, 1736, 1609, 1559, 1533, 1467, 454 
1446, 1414, 1289, 1243, 1173, 1021, 954, 837, 782, 711 cm–1. 1H NMR (250 MHz, CDCl3): δ = 2.45 455 
(s, 3 H), 3.77 (s, 3 H), 3.90 (s, 3 H), 7.05 (d, J = 8.8 Hz, 2 H), 7.28–7.34 (m, 1 H), 7.35–7.43 (m, 3 H), 456 
7.52–7.55 (m, 2 H), 8.96 (s, 1 H) ppm. 13C NMR (63 MHz, CDCl3): δ = 21.6, 30.9, 55.2, 55.5, 114.2, 457 
117.3, 123.2, 127.7, 128.2, 130.2, 131.8, 132.3, 135.9, 137.3, 144.5, 150.9, 152.5, 160.2, 160.6 ppm. 458 
HRMS (ESI): calcd. for C21H19IN3O [M + H]+456.0567; found 456.0566. 459 
 460 
5-Iodo-7-methyl-4-(3-tolyl)-6-[4-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine (7g): The 461 
reaction was carried out by following general procedure D starting from diaryl pyrimidine 6g (150 mg, 462 
0.41 mmol) to afford 7g (201.2 mg, 0.41 mmol, 100%) as a beige solid. Rf = 0.53 (CH2Cl2/ethyl 463 
acetate, 7:3); m.p. 137–139 °C (ethyl acetate). IR (ATR diamond): ν˜ = 2923, 2855, 1736, 1555, 1447, 464 
1407, 1320, 1251, 1163, 1127, 1067, 1017, 964, 911, 855, 791, 709 cm–1. 1H NMR (300 MHz, 465 
CDCl3): δ = 2.46 (s, 3 H), 3.79 (s, 3 H), 7.31–7.36 (m, 1 H), 7.38–7.45 (m, 1 H), 7.51–7.57 (m, 2 H), 466 
7.61 (d, J = 8.7 Hz, 2 H), 7.82 (d, J = 8.7 Hz, 2 H), 9.01 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ 467 
= 21.5, 30.9, 55.8, 117.1, 123.8 (J = 274 Hz), 125.7 (J = 4 Hz), 127.7, 128.0, 130.4, 131.4, 131.6, 131.7 468 
(J = 33 Hz), 134.8 (J = 1 Hz), 135.3, 137.3, 142.7, 151.2, 152.5, 160.8 ppm. 19F NMR (376 MHz, 469 
CDCl3): δ = –62.82 (CF3) ppm. HRMS (ESI): calcd. for C21H16F3IN3 [M + H]+494.0336; found 470 
494.0335. 471 
 472 
General Procedure E (Suzuki–Miyaura Coupling at C-5): Under argon, a mixture of compound 7a–g 473 
(1.0 mmol), boronic acid (1.05 mmol), sodium carbonate (2.0 mmol), and 474 
dichlorobis(triphenylphosphine) palladium (0.05 mmol) in a degassed solvent mixture of DME (3.8 mL) 475 
and H2O (0.6 mL) was transferred to a microwave reaction tube and irradiated in a microwave oven at 476 
100 °C for 60 min. The progress of the reaction was monitored by TLC. After cooling, the mixture was 477 
diluted with a mixture of brine and water (1:1, 20 mL), and the aqueous solution was extracted with 478 
 ethyl acetate (3  20 mL). Evaporation of the solvent under reduced pressure gave the crude product. A 479 
solution of the previous residue and NIS (1.1 mmol) in acetonitrile (4.5 mL) was transferred to a 480 
microwave reaction tube and irradiated in a microwave oven at 100 °C for 30 min. The progress of the 481 
reaction was monitored by TLC. After cooling, the solvent was removed, then dichloromethane (20 mL) 482 
was added and the organic layer was washed with  aqueous saturated Na2S2O3 (2  16 mL) and NaOH 483 
 (10%, 2  16 mL). Evaporation of the solvent under reduced pressure gave the crude product, which was 484 
purified by silica gel column chromatography. 485 
 486 
5-(4-Methoxyphenyl)-7-methyl-6-phenyl-4-(3-tolyl)-7H-pyrrolo-[2,3-d]pyrimidine (8a): The 487 
reaction was carried out by following general procedure E starting from the iodo derivative 7a (100 mg, 488 
0.24 mmol) and 4-methoxyphenylboronic acid (39.3 mg, 0.26 mmol). The crude product was purified by 489 
silica gel column chromatography (CH2Cl2/acetone, 95:5) to afford 8a (83.9 mg, 0.21 mmol, 88%) as a 490 
white solid (8% starting material was also recovered). Rf = 0.11 (CH2Cl2/acetone, 95:5); m.p. 144–491 
146°C (acetone). IR (ATR diamond): ν˜ = 2954, 1614, 1552, 1535, 1514, 1466, 1438, 1413, 1349, 1322, 492 
1287, 1238, 1176, 1134, 1108, 1036, 964, 919, 847, 816, 790, 762, 746 cm–1. 1H NMR (400 MHz, 493 
[D6]-DMSO): δ = 1.96 (s, 3 H), 3.64 (s, 3 H), 3.73 (s, 3 H), 6.52 (d, J = 8.8 Hz, 2 H), 6.68 (d, J = 8.8 494 
Hz, 2 H), 6.88 (s, 1 H), 7.03–7.09 (m, 2 H), 7.21–7.27 (m, 1 H), 7.35–7.39 (m, 2 H), 7.39–7.43 (m, 3 H), 495 
8.91 (s, 1 H) ppm. 13C NMR (100 MHz, [D6]DMSO): δ = 20.5, 29.6, 55.0, 112.9, 113.0, 114.2, 126.1, 496 
126.2, 127.7, 128.3, 128.7, 129.1, 130.1, 130.8, 130.9, 131.6, 136.2, 137.0, 138.9, 150.6, 151.4, 157.6, 497 
158.3 ppm. HRMS (ESI): calcd. for C27H24N3O [M + H]+406.1914; found 406.1915. 498 
 499 
7-Methyl-6-phenyl-4-(3-tolyl)-5-[4-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine (8b): 500 
The reaction was carried out by following general procedure E starting from the iodo derivative 7a (100 501 
mg, 0.24 mmol) and 4-trifluoromethylphenylboronic acid (49.1 mg, 0.26 mmol). The crude product was 502 
purified by silica gel column chromatography (CH2Cl2/acetone, 97.5:2.5 to 9:1) to afford 8b (69.8 mg, 503 
0.16 mmol, 67%) as a beige solid (29% of starting material was also recovered). Rf = 0.22 504 
(CH2Cl2/acetone, 9:1); m.p. 199–201 °C (acetone). IR (ATR diamond): ν˜ = 3043, 2921, 2847, 1618, 505 
1556, 1538, 1438, 1409, 1348, 1323, 1238, 1161, 1115, 1106, 1064, 1023, 962, 919, 856, 825, 789, 760, 506 
711, 697 cm–1. 1H NMR (400 MHz, CDCl3): δ = 1.98 (s, 3 H), 3.84 (s, 3 H), 6.85 (d, J = 8.0 Hz, 2 H), 507 
6.90 (s, 1 H), 7.04 (d, J = 6.5 Hz, 2 H), 7.16 (d, J = 8.0 Hz, 2 H), 7.22 (d, J = 6.5 Hz, 1 H), 7.24–7.28 (m, 508 
2 H), 7.39–7.41 (m, 3 H), 9.04 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 20.9, 30.1, 113.2, 509 
114.7, 124.2 (J = 4 Hz), 124.4 (J = 273 Hz), 126.4, 127.8, 128.1 (J = 32 Hz), 128.4, 128.8, 129.2, 129.8, 510 
130.0, 130.9, 131.0, 131.1, 137.3, 138.1, 139.8, 151.5, 152.4, 159.6 ppm. 19F NMR (376 MHz, CDCl3): 511 
δ = –62.55 (CF3) ppm. HRMS (ESI): calcd. for C27H21F3N3 [M + H]+ 444.1682; found 444.1683. 512 
 513 
7-Methyl-6-phenyl-4-(3-tolyl)-5-(4-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (8c): The reaction was 514 
carried out by following general procedure E starting from the iodo derivative 7a (100 mg, 0.24 mmol) 515 
and p-tolylboronic acid (35.2 mg, 0.26 mmol). The crude product was purified by silica gel column 516 
chromatography (CH2Cl2/acetone, 98:2 to 9:1) to afford 8c (64.8 mg, 0.17 mmol, 71%) as a darkbeige 517 
solid (26% of starting material was also recovered). Rf = 0.23 (CH2Cl2/acetone, 9:1); m.p. 204–206 °C 518 
(acetone). IR (ATR diamond): ν˜ = 3034, 2917, 2849, 1737, 1553, 1537, 1516, 1436, 1413, 1348, 1320, 519 
1273, 1238, 1210, 1177, 1130, 1026, 962, 918, 892, 845, 816, 788, 763, 743, 710, 698 cm–1. 1H NMR 520 
(300 MHz, CDCl3): δ = 2.00 (s, 3 H), 2.21 (s, 3 H), 3.82 (s, 3 H), 6.64 (d, J = 8.0 Hz, 2 H), 6.73 (d, J = 521 
8.0 Hz, 2 H), 6.92–7.08 (m, 3 H), 7.24–7.31 (m, 3 H), 7.33–7.40 (m, 3 H), 9.01 (s, 1 H) ppm. 13C NMR 522 
(75.5 MHz, CDCl3): δ = 21.2, 21.4, 30.3, 114.8, 115.2, 126.8, 127.7, 128.3, 128.7, 128.8, 129.6, 130.9, 523 
131.0, 131.2, 131.3, 131.4, 135.8, 137.1, 137.5, 139.2, 151.2, 152.5, 159.7 ppm. HRMS (ESI): calcd. 524 
For C27H24N3 [M + H]+ 390.1965; found 390.1964. 525 
 526 
7-Methyl-6-phenyl-4,5-bis-(3-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (8d): The reaction was carried out 527 
by following general procedure E starting from the iodo derivative 7a (100 mg, 0.24 mmol) and m-528 
tolylboronic acid (35.2 mg, 0.26 mmol). The crude product was purified by silica gel column 529 
chromatography (CH2Cl2/acetone, 98:2 to 9:1) to afford 8d (69.6 mg, 0.18 mmol, 76%) as a white solid 530 
(22% of starting material was also recovered). Rf = 0.09 (CH2Cl2/acetone, 9:1); m.p. 151–153 °C 531 
(acetone). IR (ATR diamond): ν˜ = 3028, 2919, 2847, 1557, 1538, 1492, 1463, 1441, 1418, 1349, 1324, 532 
1241, 1193, 1166, 1128, 1086, 1025, 1000, 969, 924, 901, 870, 839, 812, 788, 763, 748, 719, 703 cm–1. 533 
1H NMR (300 MHz, CDCl3): δ = 1.93 (s, 3 H), 2.03 (s, 3 H), 3.82 (s, 3 H), 6.50 (s, 1 H), 6.60 (d, J = 534 
7.1 Hz, 1 H), 6.78–6.86 (m, 2 H), 7.01–7.04 (m, 3 H), 7.21–7.23 (m, 1 H), 7.26–7.32 (m, 2 H), 7.34–535 
7.39 (m, 3 H), 9.02 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 21.1, 30.0, 114.7, 115.0, 126.5, 536 
126.8, 127.3, 127.4, 127.7, 128.5, 128.7, 129.4, 130.7, 130.9, 131.1, 132.3, 133.7, 136.9, 137.6, 139.0, 537 
151.1, 152.3, 159.7 ppm. HRMS (ESI): calcd. for C27H24N3 [M + H]+ 390.1965; found 390.1967.  538 
 539 
7-Methyl-6-phenyl-4-(3-tolyl)-5-(2-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (8e): The reaction was 540 
carried out by following general procedure E starting from the iodo derivative 7a (100 mg, 0.24 mmol, 541 
1.0 equiv.) and p-tolylboronic acid (35.2 mg, 0.26 mmol, 1.1 equiv.). The product was purified by 542 
chromatography on silica gel (CH2Cl2/ acetone, 98:2 to 9:1) to afford starting material (82 %). Product 543 
8e was not observed. 544 
 545 
5-(4-Methoxyphenyl)-7-methyl-6-phenyl-4-(2-tolyl)-7H-pyrrolo-[2,3-d]pyrimidine (8f): The 546 
reaction was carried out by following general procedure E starting from the iodo derivative 7b (100 mg, 547 
0.24 mmol) and 4-methoxyphenylboronic acid (39.3 mg, 0.26 mmol). The crude product was purified by 548 
silica gel column chromatography (CH2Cl2/acetone, 98:2 to 9:1) to afford 8f (89.5 mg, 0.22 mmol, 549 
94%) as a beige solid (5% of starting material was also recovered). Rf = 0.42 (CH2Cl2/acetone, 9:1); 550 
m.p. 186–188 °C (acetone). IR (ATR diamond): ν˜ = 3060, 2997, 2931, 1609, 1559, 1513, 1415, 1349, 551 
1319, 1287, 1243, 1224, 1179, 1121, 1033, 953, 894, 837, 809, 774, 763, 729, 701 cm–1. 1H NMR (400 552 
MHz, CDCl3): δ = 1.99 (s, 3 H), 3.65 (s, 3 H), 3.83 (s, 3 H), 6.34 (d, J = 8.6 Hz, 2 H), 6.55 (d, J = 8.6 553 
Hz, 2 H), 6.94 (t, J = 7.4 Hz, 2 H), 7.01 (d, J = 7.4 Hz, 1 H), 7.09 (t, J = 7.4 Hz, 1 H), 7.26–7.28 (m, 2 554 
H), 7.34–7.36 (m, 3 H), 9.00 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 19.8, 30.0, 55.2, 112.7, 555 
114.4, 116.3, 125.1, 125.2, 128.3, 128.6, 128.7, 129.4, 129.7, 130.6, 131.1, 131.5, 135.8, 137.7, 138.9, 556 
151.1, 151.8, 157.7, 160.1 ppm. HRMS (ESI): calcd. For C27H24N3O [M + H]+ 406.1914; found 557 
406.1913. 558 
 559 
5-(4-Methoxyphenyl)-7-methyl-6-phenyl-4-(4-tolyl)-7H-pyrrolo-[2,3-d]pyrimidine (8g): The 560 
reaction was carried out by following general procedure E starting from the iodo derivative 7c (100 mg, 561 
0.24 mmol) and 4-methoxyphenylboronic acid (39.3 mg, 0.26 mmol). The crude product was purified by 562 
silica gel column chromatography (CH2Cl2/acetone, 98:2 to 9:1) to afford 8g (61.9 mg, 0.15 mmol, 563 
65%) as a beige solid (29% of starting material was also recovered). Rf = 0.21 (CH2Cl2/acetone, 8:2); 564 
m.p. 157–159 °C (acetone). IR (ATR diamond): ν˜ = 2917, 2849, 1550, 1532, 1510, 1462, 1440, 1418, 565 
1346, 1321, 1290, 1237, 1174, 1132, 1110, 1035, 953, 892, 831, 800, 783, 767, 713, 704 cm–1. 1H 566 
NMR (300 MHz, CDCl3): δ = 2.27 (s, 3 H), 3.69 (s, 3 H), 3.81 (s, 3 H), 6.46 (d, J = 8.7 Hz, 2 H), 6.64 567 
(d, J = 8.7 Hz, 2 H), 6.87 (d, J = 8.0 Hz, 2 H), 7.19 (d, J = 8.0 Hz, 2 H), 7.25–7.29 (m, 2 H), 7.32–7.45 568 
(m, 3 H), 9.00 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 21.4, 29.9, 55.3, 113.0, 114.2, 115.0, 569 
126.4, 128.0, 128.5, 128.6, 129.6, 130.7, 131.1, 131.9, 134.7, 138.5, 138.9, 151.0, 152.2, 158.0, 159.4 570 
ppm. HRMS (ESI): calcd. for C27H24N3O [M + H]+406.1914; found 406.1916. 571 
 572 
4,5-Bis(4-methoxyphenyl)-7-methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine (8h): The reaction was 573 
carried out by following general procedure E starting from the iodo derivative 7d (100 mg, 0.23 mmol) 574 
and 4-methoxyphenylboronic acid (37.9 mg, 0.25 mmol). The crude product was purified by silica gel 575 
column chromatography (CH2Cl2/acetone, 98:2 to 9:1) to afford 8h (87.7 mg, 0.21 mmol, 92%) as an 576 
off-white solid (6% of starting material was also recovered). Rf = 0.39 (CH2Cl2/acetone, 8:2); m.p. 577 
172–174 °C (acetone). IR (ATR diamond): ν˜ = 3039, 2923, 2832, 1605, 1552, 1532, 1510, 1455, 1435, 578 
1416, 1347, 1322, 1301, 1289, 1246, 1235, 1173, 1130, 1108, 1034, 954, 927, 892, 842, 804, 783, 768, 579 
704 cm–1. 1H NMR (400 MHz, CDCl3): δ = 3.71 (s, 3 H), 3.74 (s, 3 H), 3.81 (s, 3 H), 6.50 (d, J = 8.8 580 
Hz, 2 H), 6.59 (d, J = 8.8 Hz, 2 H), 6.67 (d, J = 8.8 Hz, 2 H), 7.24–7.29 (m, 4 H), 7.34–7.39 (m, 3 H), 581 
8.98 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 30.0, 55.3, 55.4, 112.9, 113.1, 114.2, 114.8, 582 
126.6, 128.5, 128.6, 130.2, 130.8, 131.2, 131.3, 132.0, 138.8, 151.1, 152.3, 158.1, 159.0, 160.3 ppm. 583 
HRMS (ESI): calcd. for C27H24N3O2 [M + H]+ 422.1863; found 422.1864.  584 
 585 
5-(4-Methoxyphenyl)-7-methyl-6-phenyl-4-[4-(trifluoromethyl)-phenyl]-7H-pyrrolo[2,3-586 
d]pyrimidine (8i): The reaction was carried out by following general procedure E starting from the iodo 587 
derivative 7e (100 mg, 0.21 mmol) and 4-methoxyphenylboronic acid (34.9 mg, 0.23 mmol). The crude 588 
product was purified by silica gel column chromatography (CH2Cl2/acetone, 98:2 to 9:1) to afford 8i 589 
(71.4 mg, 0.16 mmol, 74%) as a fluorescent yellow solid (20% of starting material was also recovered). 590 
Rf = 0.5 (CH2Cl2/acetone, 8:2); m.p. 198–200 °C (acetone). IR (ATR diamond): ν˜ = 3038, 2935, 2832, 591 
1612, 1557, 1513, 1484, 1470, 1442, 1406, 1349, 1318, 1290, 1246, 1232, 1172, 1158, 1119, 1104, 592 
1064, 1037, 1017, 953, 926, 895, 846, 804, 780, 763, 748, 734, 703 cm–1. 1H NMR (400 MHz, 593 
CDCl3): δ = 3.67 (s, 3 H), 3.84 (s, 3 H), 6.45 (d, J = 8.7 Hz, 2 H), 6.60 (d, J = 8.7 Hz, 2 H), 7.27–7.34 594 
(m, 4 H), 7.36–7.40 (m, 5 H), 9.03 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 30.1, 55.2, 113.2, 595 
113.8, 115.6, 124.2 (J = 273 Hz), 124.2 (J = 4 Hz), 125.8, 128.6, 128.9, 129.9, 130.3, 130.4 (J = 32 Hz), 596 
131.0, 131.8, 139.5, 141.1, 151.2, 152.3, 157.7, 158.4 ppm. 19F NMR (376 MHz, CDCl3): δ = –62.70 597 
(CF3) ppm. HRMS (ESI): calcd. for C27H21F3N3O [M + H]+ 460.1631; found 460.1632. 598 
 599 
5,6-Bis(4-methoxyphenyl)-7-methyl-4-(3-tolyl)-7H-pyrrolo[2,3-d]pyrimidine (8j): The reaction was 600 
carried out by following general procedure E starting from the iodo derivative 7f (100 mg, 0.22 mmol) 601 
and 4-methoxyphenylboronic acid (36.7 mg, 0.24 mmol). The crude product was purified by silica gel 602 
column chromatography (CH2Cl2/acetone, 98:2 to 8:2) to afford 8j (54.6 mg, 0.13 mmol, 57%) as a 603 
beige solid (40% of starting material was also recovered). Rf = 0.20 (CH2Cl2/acetone, 9:1); m.p. 195–604 
197 °C (acetone). IR (ATR diamond): ν˜ = 3033, 2921, 2850, 1738, 1612, 1541, 1519, 1496, 1463, 605 
1442, 1422, 1394, 1346, 1319, 1292, 1242, 1174, 1132, 1108, 1028, 961, 933, 917, 852, 835, 810, 798, 606 
784, 741, 725, 709 cm–1. 1H NMR (300 MHz, CDCl3): δ = 2.04 (s, 3 H), 3.70 (s, 3 H), 3.81 (2s, 6 H), 607 
6.48 (d, J = 8.9 Hz, 2 H), 6.66 (d, J = 8.9 Hz, 2 H), 6.89 (d, J = 8.9 Hz, 2 H), 7.00–7.06 (m, 3 H), 7.19 608 
(d, J = 8.9 Hz, 2 H), 7.21–7.24 (m, 1 H), 8.99 (s, 1 H) ppm. 13C NMR (75.5 MHz, CDCl3): δ = 21.1, 609 
30.0, 55.3, 55.4, 113.0, 113.8, 114.0, 115.0, 122.7, 126.6, 126.7, 127.4, 129.3, 131.0, 131.9, 132.3, 610 
137.0, 137.4, 138.9, 150.8, 152.2, 157.9, 159.1, 159.7 ppm. HRMS (ESI): calcd. for C28H26N3O2 [M + 611 
H]+ 436.2020; found 436.2020. 612 
 613 
5-(4-Methoxyphenyl)-7-methyl-4-(3-tolyl)-6-[4-(trifluoromethyl)-phenyl]-7H-pyrrolo[2,3-614 
d]pyrimidine (8k): The reaction was carried out by following general procedure E starting from the 615 
iodo derivative 7g (150 mg, 0.30 mmol) and 4-methoxyphenylboronic acid (50.8 mg, 0.36 mmol). The 616 
crude product was purified by silica gel column chromatography (CH2Cl2/acetone, 95:5) to afford 8k 617 
(84.5 mg, 0.18 mmol, 59%) as a white solid (34% of starting material was also recovered). Rf = 0.39 618 
(CH2Cl2/acetone, 7:3); m.p. 191–193 °C (acetone). IR (ATR diamond): ν˜ = 3055, 2955, 2923, 2854, 619 
1708, 1557, 1539, 1514, 1438, 1416, 1349, 1319, 1287, 1243, 1224, 1179, 1120, 1086, 1033, 953, 894, 620 
837, 809, 773, 763, 722, 701 cm–1. 1H NMR (400 MHz, CDCl3): δ = 2.05 (s, 3 H), 3.71 (s, 3 H), 3.83 621 
(s, 3 H), 6.51 (d, J = 8.8 Hz, 2 H), 6.65 (d, J = 8.8 Hz, 2 H), 6.96–7.06 (m, 3 H), 7.21–7.25 (m, 1 H), 622 
7.40 (d, J = 8.0 Hz, 2 H), 7.63 (d, J = 8.0Hz, 2 H), 9.02 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 623 
21.1, 30.2, 55.3, 113.3, 115.0, 115.3, 124.0 (J = 274 Hz), 125.5 (J = 4 Hz), 125.9, 126.7, 127.5, 129.6, 624 
130.4, 130.7, 131.0, 131.5, 131.9, 134.6 (J = 1 Hz), 137.1, 137.2, 151.6, 152.5, 158.3, 160.2 ppm. 19F 625 
NMR (376 MHz, CDCl3): δ = –62.73 (CF3) ppm. HRMS (ESI): calcd. for C28H23F3N3O [M + 626 
H]+474.1788; found 474.1787. CCDC-963176 contains the supplementary crystallographic data for this 627 
paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via 628 
www.ccdc.cam.ac.uk/data_request/cif. 629 
 630 
4-Chloro-5-(4-methoxyphenyl)-7-methyl-6-phenyl-7H-pyrrolo[2,3-d]-pyrimidine (9): The reaction 631 
was carried out by following general procedure E starting from 10 (150 mg, 10a: 0.46mmol or 10b: 0.41 632 
mmol) and 4-methoxyphenylboronic acid (10a: 77.5mg, 0.51 mmol or 10b: 68.4 mg, 0.45 mmol). The 633 
crude product was purified by silica gel column chromatography (CH2Cl2/acetone, 95:5) to afford 9 as 634 
a white solid in 33% (53.5 mg, 0.15 mmol from 10a) and 70% (99.2 mg, 0.28 mmol from 10b) yield. Rf 635 
= 0.35 (CH2Cl2/acetone, 95:5); m.p. 150–152 °C (acetone). IR (ATR diamond): ν˜ = 2931, 2836, 1541, 636 
1515, 1479, 1445, 1414, 1286, 1247, 1234, 1220, 1178, 1155, 1124, 1028, 955, 892, 834, 750, 708, 700 637 
cm–1. 1H NMR (250 MHz, CDCl3): δ = 3.81 (s, 3 H), 3.83 (s, 3 H), 6.83 (d, J = 8.8 Hz, 2 H), 7.19 (d, J 638 
= 8.8 Hz, 2 H), 7.25–7.34 (m, 2 H), 7.36–7.45 (m, 3 H), 8.70 (s, 1 H) ppm. 13C NMR (75.5 MHz, 639 
CDCl3): δ = 33.4, 55.3, 113.1, 113.9, 115.8, 124.6, 128.6, 128.9, 129.8, 130.8, 132.9, 140.0, 150.3, 640 
151.7, 151.8, 158.7 ppm. HRMS (ESI): calcd. for C20H17ClN3O [M + H]+350.1055; found 350.1055. 641 
 642 
5-Bromo-4-chloro-7-methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine (10a): A solution of 4-643 
chloropyrimidine 5a (750 mg, 3.08 mmol) and NBS (639 mg, 3.59 mmol) in acetonitrile (5.5 mL) was 644 
transferred to a special microwave tube and irradiated in a microwave oven at 100 °C for 30 min. The 645 
progress of the reaction was monitored by TLC. After cooling, the solvent was removed under vacuo. 646 
Dichloromethane (20 mL) was added and the organic layer was washed with aqueous saturated 647 
 Na2S2O3 (2  16 mL), and NaOH  (10%, 2  16 mL). Evaporation of the solvent under reduced pressure 648 
gave the crude product 10a (874.6 mg, 2.71 mmol, 87%) as a yellow solid, which did not require further 649 
purification. Rf = 0.41 (CH2Cl2/ethyl acetate, 9:1); m.p. 168–170 °C (ethyl acetate). IR (ATR 650 
diamond): ν˜ = 3059, 2931, 1582, 1544, 1488, 1468, 1436, 1347, 1221, 1174, 1152, 1028, 962, 890, 780, 651 
762, 701 cm–1. 1H NMR (250 MHz, CDCl3): δ = 3.75 (s, 3 H), 7.47–7.58 (m, 5 H), 8.66 (s, 1 H) ppm. 652 
13C NMR (63 MHz, CDCl3): δ = 30.9, 87.3, 115.3, 128.7, 129.0, 130.0, 130.6, 140.8, 150.9, 151.3, 653 
151.8 ppm. HRMS (ESI): calcd. for C13H10BrClN3 [M + H]+ 321.9741; found 321.9742. 654 
4-Chloro-5-iodo-7-methyl-6-phenyl-7H-pyrrolo[2,3-d]pyrimidine (10b): The reaction was carried 655 
out by following general procedure D starting from 4-chloropyrimidine (5a) (300 mg, 1.23 mmol, 1.0 656 
equiv.) to afford 10b (435.5 mg, 1.18 mmol, 96%) as a yellow solid. Rf = 0.34 (CH2Cl2/ethyl acetate, 657 
95:5); m.p. 203–205 °C (ethyl acetate). IR (ATR diamond): ν˜ = 3744, 3058, 2924, 2854, 1541, 1479, 658 
1434, 1343, 1265, 1217, 1168, 1026, 952, 886, 765, 702 cm–1. 1H NMR (400 MHz, CDCl3): δ = 3.73 659 
(s, 3 H), 7.41–7.47 (m, 2 H), 7.53–7.58 (m, 3 H), 8.64 (s, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 660 
31.4, 54.0, 117.5, 129.0, 130.1, 130.5, 130.8, 144.8, 150.6, 152.2, 152.4 ppm. HRMS (ESI): calcd. for 661 
C13H10ClIN3 [M + H]+ 369.9603; found 369.9604. 662 
 663 
 664 
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Scheme 4. Diarylation of pyrrolopyrimidines. 751 
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Figure 2. Molecular structure of 8k. Displacement ellipsoids are drawn at the 30% probability level and 753 
H atoms are represented by circles of arbitrary radii. 754 
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Table 1. Suzuki–Miyaura cross-coupling reactions at the 4-position of heterocycle 5 leading to 4,6-791 





  797 






  804 
Table 3. Suzuki–Miyaura cross-coupling reaction at C-5 of pyrrolopyrimidines 7.. 805 
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